Compare YPF & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YPF | JAZZ |
|---|---|---|
| Founded | 1977 | 2003 |
| Country | Argentina | Ireland |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4B | 16.1B |
| IPO Year | 1995 | 2007 |
| Metric | YPF | JAZZ |
|---|---|---|
| Price | $37.18 | $244.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 22 |
| Target Price | $60.78 | ★ $295.86 |
| AVG Volume (30 Days) | ★ 1.3M | 771.2K |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $58.16 | $12.59 |
| Revenue Next Year | N/A | $5.11 |
| P/E Ratio | ★ N/A | $6,151.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.74 | $136.56 |
| 52 Week High | $57.87 | $266.38 |
| Indicator | YPF | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 21.37 | 65.72 |
| Support Level | $36.04 | $236.70 |
| Resistance Level | $39.96 | $250.49 |
| Average True Range (ATR) | 2.02 | 7.18 |
| MACD | -1.06 | 4.64 |
| Stochastic Oscillator | 4.73 | 95.81 |
YPF SA is an Argentina-based integrated oil and gas company. The company operates through four business segments: Upstream, Midstream and Downstream, LNG and Integrated Gas, and New Energies. The Upstream segment focuses on the exploration and production of crude oil and natural gas. The Midstream and Downstream segment includes refining, transportation, and commercialization of crude oil, refined, and petrochemical products. The LNG and Integrated Gas segment is involved in natural gas transportation, processing, storage, and commercialization. The New Energies segment focuses on energy transition initiatives, including natural gas distribution, power generation, renewable energy, and related technology development. It generates majority of revenue from Midstream and Downstream segment.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.